Comparative Pharmacology
Head-to-head clinical analysis: OXALIPLATIN versus TREANDA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OXALIPLATIN versus TREANDA.
OXALIPLATIN vs TREANDA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oxaliplatin is a platinum-based alkylating agent that forms inter- and intrastrand DNA crosslinks, inhibiting DNA replication and transcription, leading to cell death.
Bendamustine is a bifunctional mechlorethamine derivative that forms electrophilic alkyl groups which covalently bond to DNA bases, resulting in interstrand DNA crosslinks, DNA single- and double-strand breaks, and ultimately apoptosis. It also inhibits several mitotic checkpoints and induces both apoptosis and necrosis in cancer cells.
85 mg/m² intravenously over 2 hours every 2 weeks in combination with 5-fluorouracil and leucovorin (FOLFOX regimen).
120 mg/m2 IV over 60 minutes on Days 1 and 2 of a 21-day cycle.
None Documented
None Documented
Clinical Note
moderateOxaliplatin + Digoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateOxaliplatin + Digitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateOxaliplatin + Deslanoside
"Oxaliplatin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateOxaliplatin + Acetyldigitoxin
"Oxaliplatin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life is approximately 40-50 hours for ultrafilterable platinum (active species) and 240-500 hours for total platinum (bound to plasma proteins and erythrocytes). The prolonged half-life reflects slow release from tissue binding.
Terminal elimination half-life: ~36-40 minutes (active metabolite M3: ~3 hours). Short half-life supports multi-day dosing regimens; clinical effect duration is longer due to DNA alkylation.
Renal excretion accounts for approximately 50% of the administered platinum, with the remainder eliminated via biliary/fecal routes. Platinum accumulates in erythrocytes and is slowly cleared.
Renal: ~50% as unchanged drug and metabolites; additional biliary/fecal elimination (non-renal clearance accounts for ~50% in humans, but specific biliary/fecal percentages not routinely quantified in clinical studies).
Category D/X
Category C
Alkylating Agent
Alkylating Agent